The nitric-oxide skin therapeutics developer will use the proceeds to fund late-stage clinical trials for acne, skin infection and fungal infection treatments.
Novan Therapeutics, a US-based dermatology treatment developer backed by life sciences company Malin Corporation, filed for an initial public offering last week and is aiming to raise up to $60m.
Founded in 2008 as a spinout of University of North Carolina at Chapel Hill, Novan is working on dermatology treatments that will use nitric oxide to regulate skin inflammation. It is developing treatments for five separate dermatological conditions.
The proceeds will be used to advance Novan’s lead product candidate,…
